by Cherry Salazar | Sep 22, 2025
Moderna, which led the biotechnology sector’s pandemic-driven surge, struggles to keep pace with the market. Moderna, Inc.’s windfall during the pandemic has now become its headwind. Once propelled to record highs by its breakthrough messenger RNA technology, the...
by Laura Turbay | Nov 13, 2024
Eli Lilly lowered its revenue forecasts for the full year after an inventory drawdown by wholesalers weighed on sales for blockbuster weight loss and diabetes drugs. The stock fell 13% when markets opened on Wednesday. Both Mounjaro and Zepbound missed...
by Laura Turbay | Nov 13, 2024
The race to supply weight-loss drugs to nearly half of Americans that classify as obese, is on. Eli Lilly’s stock boomed after they released their blockbuster weight loss drug Zepbound last year, consecrating the Indiana-based drugmaker as one of the top...
by Laura Turbay | Sep 23, 2024
Small-cap biotech stocks plundered after a 2021 wild-run, but investors are hopeful that interest rate cuts and positive test results in oncology and autoimmune treatments will be the right prescription for the biopharma market. That would be welcome news for...
by Mariam Kiparoidze | Nov 27, 2023
Photo: Wikimedia Commons Covid made Pfizer a household name and sent its revenues and profits soaring. Now flush with cash and amid its post-covid slump, Pfizer is betting that its next blockbuster drug could be a cancer treatment. The pharma giant made headlines...
by Mariam Kiparoidze | Nov 3, 2023
Photo credit:Wikimedia Commons Pfizer reported a loss in the third quarter as it tries to adapt to the faltering demand on its Covid-19 drug and vaccines. Pfizer reported a net loss of $2.38 billion last quarter, missing analyst expectations, the pharmaceutical giant...
